- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05641701
Stimulation of the Thalamus to Ameliorate Persistent Disfluency (SToPeD)
Stimulation of the Thalamus to Ameliorate Persistent Disfluency: Pilot Study
Persistent developmental stutter / childhood onset fluency disorder is a disabling condition leading to significant communication and psychological disability. Established treatment consists of intensive speech therapy, and whilst initially effective, has a waning long-term benefit.
Our research team aims to provide evidence of stutter management by addressing the primary neurological issue in this disorder using Deep Brain Stimulation. The investigators propose to perform bilateral DBS on 3 participants with stutter refractory to intensive speech therapy, to determine a response in their stutter. The assessments will be double-blinded. The investigators will use the outcome of this small pilot study to determine the feasibility and details of a larger randomized controlled trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Suitable participants are referred by speech pathology centers, after having failed an intensive speech therapy program. Referred participants are contacted by the Neurosurgery DBS Clinic, and assessed for suitability and willingness to participate.
These potential participants will be contacted by the DBS Clinic at Vancouver General Hospital to discuss the scope of the study, and educate them about deep brain stimulation. Those who wish to be included in the study will attend a face-to-face appointment at the DBS Clinic.
At the initial appointment, informed consent will take place. Baseline assessments will be undertaken, including the Overall Assessment of the Speaker's Experience of Stuttering (OASES), Voice-related Quality of Life (VRQoL), and "The One Page Stuttering Assessment". The participants will be referred for a functional MRI for mapping of speech and language laterality.
The participants will then undergo surgery for implantation of a bilateral thalamic DBS system. They will stay overnight in the hospital, and have a post-operative CT scan on the first post-operative day. This scan will be used to assess accuracy of electrode placement, as per usual technique.
4 weeks post-operatively, the participants will attend the DBS Clinic for programming of their devices.
4 weeks after device programming, the participants will attend the DBS clinic for 1-page stutter assessment with bilateral electrodes on, bilateral electrodes off, left electrode on, and right electrode on, as well as OASES and VRQoL.
The scores from the 1-page stutter assessment, as well as pre- and post-operative OASES and VRQoL, will be compared via the Wilcoxan rank sum test for nonparametric repeated measures.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Danielle Pietramala
- Phone Number: 68396 604-875-4111
- Email: danielle.pietram@ubc.ca
Study Contact Backup
- Name: Christopher R Honey
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults between the ages of 19 and 76 years old
- Individuals with persistent developmental stutter refractory to intensive speech therapy, as diagnosed by a speech and language therapist.
Exclusion Criteria:
- Children and adolescents will not be included, as there is a significant percentage of developmental stuttering that will spontaneously resolve in this age group.
- Patients who have not trialed standard therapy will not be included in this study.
- Patients with mild symptoms.
- Patients who have a neurodegenerative disease.
- Patients with a bleeding diathesis.
- Patients who are unable to communicate.
MRI Specific Exclusion criteria:
- Patients with a cardiac pacemaker or defibrillator.
- Patient with an insulin or infusion pump.
- Patients with a cochlear, otologic, or ear implant.
- Patients with an implant held in place by a magnet.
- Patients with tissue expanders.
- Patients with implanted clips, catheters, clamps, valves, or other metal.
- Patients with tattoos or permanent makeup above shoulders.
- Patients with shrapnel or other retained metal.
- Patients who are pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deep Brain Simulation (DBS) System
The DBS device will be turned on to compare stutter to when the device was off (which would be the control).
|
The DBS system will be turned on, and the individual's stutter will be assessed.
The DBS system will be turned off, and the individual's stutter will be assessed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of One-Page Suttering Assessment from Baseline to Post-Operation
Time Frame: Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic for 1-page stutter assessment with bilateral electrodes on.
|
Objectively assesses individual's stutter.
Divide the number of instances of stuttering by the number of syllables in the sample and multiply by 100 to obtain the percentage of stuttered syllables.
|
Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic for 1-page stutter assessment with bilateral electrodes on.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Voice Related Quality of Life (VRQoL) from Baseline to Post-Operation
Time Frame: Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses quality of life post surgery.
|
A 10-question, 5 point rating scale assessment, with higher scores reflecting a worse subjective voice-related quality of life.
|
Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses quality of life post surgery.
|
Change of Overall Assessment of the Speaker's Experience of Stuttering (OASES) from Baseline to Post-Operation
Time Frame: Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses subjective voice experience post surgery.
|
5-point scale that indicates the amount of adverse impact a person experiences due to stuttering, with higher scores indicating higher levels of negative impact.
|
Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses subjective voice experience post surgery.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H22-02984
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent Developmental Stutter
-
Pharmacology Research InstituteCompletedPersistent Developmental StutteringUnited States
-
HaEmek Medical Center, IsraelRecruitingPersistent Developmental StutteringIsrael
-
Endo PharmaceuticalsCompletedPersistent Developmental StutteringUnited States
-
Universidad Autonoma de Nuevo LeonHospital Universitario Dr. Jose E. GonzalezRecruitingPersistent Epithelial DefectMexico
-
Aarhus University HospitalCompleted
-
Amber Ophthalmics, Inc.RecruitingPersistent Corneal Epithelial DefectUnited States
-
Radboud University Medical CenterWageningen University and Research; Movisie; Municipality of Meppel, the Netherlands and other collaboratorsCompletedPerceived Stress | Persistent PovertyNetherlands
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechTerminatedPersistent Corneal Epithelial DefectUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPersistent Corneal Epithelial DefectJapan
-
Hanan JafarCompletedPersistent Corneal Epithelial DefectJordan
Clinical Trials on System On
-
University of Warmia and Mazury in OlsztynRegional Specialized Hospital in OlsztynCompletedNeuromuscular BlockadePoland
-
Philips Electronics Nederland B.V. acting through...CompletedNeuromuscular DiseasesNetherlands
-
ReShape LifesciencesCompletedObesityUnited States, Australia
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Completed
-
Baxter Healthcare CorporationGambro Renal Products, Inc.Completed
-
Ajou University School of MedicineCompleted
-
Cochlear Bone Anchored SolutionsCompletedSingle Sided Sensorineural Deafness | Mixed Hearing Loss, UnilateralDenmark, Spain, United Kingdom, Belgium
-
AdventHealthHalyard HealthCompletedPain, Postoperative | Anesthesia, LocalUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingAcute Ischemic Stroke | Quality Improvement | Stroke RecrudescenceChina